• Regeneron Pharmaceuticals Inc REGN.OQ reported quarterly adjusted earnings of $8.22​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $9.55. The mean expectation of twenty one analysts for the quarter was for earnings of $8.82 per share. Wall Street expected results to range from $6.11 to $12.30 per share.

• Revenue fell 3.7% to $3.03 billion from a year ago; analysts expected $3.27 billion.

• Regeneron Pharmaceuticals Inc's reported EPS for the quarter was $7.27​.

• The company reported quarterly net income of $808.7 million.

• Regeneron Pharmaceuticals Inc shares had fallen by 3.7% this quarter and lost 14.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 14% in the last three months.​

• In the last 30 days, fifteen analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 7 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Regeneron Pharmaceuticals Inc is $917.00

This summary was machine generated from LSEG data April 29 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)